The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | First-in-human Phase I trial of AT101, a novel anti-CD19 CAR-T, in R/R NHL
In this video, Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, introduces AT101, a novel anti-CD19 CAR T-cell product with unique characteristics. Dr Ruella comments on the promising results of the first-in-human Phase I clinical trial (NCT05338931) investigating this product in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Inventor: CART technologies, Univ. of Pennsylvania, partly licensed to Novartis, Tmunity, and
viTToria biotherapeutics;
Research Funding: AbClon, Beckman-Coulter, ONI, Lumicks, viTToria bio;
DSMB: PeproMene;
Consultancy/Honoraria: GLG, Guidepoint;
Advisory Board: viTToria bio, AbClon, BMS, Sana, GSK, Bayer;
Scientific Founder: viTToria biotherapeutics.
